Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, Antonio Jimeno, Cindy L. O'Bryant, Ramesh K. Ramanathan, Glen J. Weiss, Manpreet Chadha, Abbie Oey, Han Ting Ding, Patricia A. Culp, Stephan F. Keller, Vivian Y. Zhao, L. Claire Tsao, Anil Singhal, Kyle D. Holen, Daniel Von Hoff

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences